Effects of prolonged anesthesia with enflurane or halothane on renal function in dogs. 1981

I Wickström, and T Stefansson

Elevated serum inorganic fluoride levels (60-300 mumol/l), maintained over 6 h, influenced renal function in beagle dogs. Changes in water reabsorption were seen with an increased urine flow and free water clearance and decreased urinary concentration capacity. Possible nephrotoxicity as an effect of inorganic fluoride production during prolonged enflurane anesthesia was evaluated in a group of beagle dogs. Another group of dogs, anesthetized with halothane in equianesthetic doses, was studied for comparison. Serum inorganic fluoride levels and urinary oxalate excretion were determined and postanesthetic renal morphology was examined. Renal function was evaluated from endogenous clearances and concentration capacity before and after anesthesia. In the enflurane group, serum inorganic fluoride levels peaked at 22.5 mumol/l at the end of anesthesia and decreased rapidly in the postanesthetic period. Urinary oxalate excretion did not increase. No changes in renal morphology were found. Renal function tests did not reveal any disturbance after enflurane anesthesia. The two anesthetized groups did not differ in any of the parameters studied, except in serum inorganic fluoride levels.

UI MeSH Term Description Entries
D007668 Kidney Body organ that filters blood for the secretion of URINE and that regulates ion concentrations. Kidneys
D007671 Kidney Concentrating Ability The ability of the kidney to excrete in the urine high concentrations of solutes from the blood plasma. Urine Concentrating Ability,Abilities, Kidney Concentrating,Abilities, Urine Concentrating,Ability, Kidney Concentrating,Ability, Urine Concentrating,Concentrating Abilities, Kidney,Concentrating Abilities, Urine,Concentrating Ability, Kidney,Concentrating Ability, Urine,Kidney Concentrating Abilities,Urine Concentrating Abilities
D010070 Oxalates Derivatives of OXALIC ACID. Included under this heading are a broad variety of acid forms, salts, esters, and amides that are derived from the ethanedioic acid structure. Oxalate,Ethanedioic Acids,Oxalic Acids,Acids, Ethanedioic,Acids, Oxalic
D004285 Dogs The domestic dog, Canis familiaris, comprising about 400 breeds, of the carnivore family CANIDAE. They are worldwide in distribution and live in association with people. (Walker's Mammals of the World, 5th ed, p1065) Canis familiaris,Dog
D004737 Enflurane An extremely stable inhalation anesthetic that allows rapid adjustments of anesthesia depth with little change in pulse or respiratory rate. Alyrane,Enfran,Enlirane,Ethrane,Etran
D005459 Fluorides Inorganic salts of hydrofluoric acid, HF, in which the fluorine atom is in the -1 oxidation state. (McGraw-Hill Dictionary of Scientific and Technical Terms, 4th ed) Sodium and stannous salts are commonly used in dentifrices. Fluoride
D006221 Halothane A nonflammable, halogenated, hydrocarbon anesthetic that provides relatively rapid induction with little or no excitement. Analgesia may not be adequate. NITROUS OXIDE is often given concomitantly. Because halothane may not produce sufficient muscle relaxation, supplemental neuromuscular blocking agents may be required. (From AMA Drug Evaluations Annual, 1994, p178) 1,1,1-Trifluoro-2-Chloro-2-Bromoethane,Fluothane,Ftorotan,Narcotan
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D013997 Time Factors Elements of limited time intervals, contributing to particular results or situations. Time Series,Factor, Time,Time Factor
D019815 Oxalic Acid A strong dicarboxylic acid occurring in many plants and vegetables. It is produced in the body by metabolism of glyoxylic acid or ascorbic acid. It is not metabolized but excreted in the urine. It is used as an analytical reagent and general reducing agent. Aluminum Oxalate,Ammonium Oxalate,Chromium (2+) Oxalate,Chromium (3+) Oxalate (3:2),Chromium Oxalate,Diammonium Oxalate,Dilithium Oxalate,Dipotassium Oxalate,Disodium Oxalate,Ferric Oxalate,Iron (2+) Oxalate (1:1),Iron (3+) Oxalate,Iron Oxalate,Magnesium Oxalate,Magnesium Oxalate (1:1),Manganese (2+) Oxalate (1:1),Monoammonium Oxalate,Monohydrogen Monopotassium Oxalate,Monopotassium Oxalate,Monosodium Oxalate,Potassium Chromium Oxalate,Potassium Oxalate,Potassium Oxalate (2:1),Sodium Oxalate,Acid, Oxalic,Oxalate, Aluminum,Oxalate, Chromium,Oxalate, Diammonium,Oxalate, Dilithium,Oxalate, Dipotassium,Oxalate, Disodium,Oxalate, Ferric,Oxalate, Iron,Oxalate, Magnesium,Oxalate, Monoammonium,Oxalate, Monohydrogen Monopotassium,Oxalate, Monopotassium,Oxalate, Monosodium,Oxalate, Potassium,Oxalate, Potassium Chromium,Oxalate, Sodium

Related Publications

I Wickström, and T Stefansson
January 1976, Acta anaesthesiologica Belgica,
I Wickström, and T Stefansson
February 1984, Anesthesiology,
I Wickström, and T Stefansson
December 1978, Anesthesiology,
I Wickström, and T Stefansson
April 1980, Anesthesia and analgesia,
I Wickström, and T Stefansson
June 1978, L'union medicale du Canada,
I Wickström, and T Stefansson
November 1986, Masui. The Japanese journal of anesthesiology,
I Wickström, and T Stefansson
August 1990, Masui. The Japanese journal of anesthesiology,
Copied contents to your clipboard!